Oncternal Therapeutics (ONCT) SEC Filings & 10K Form $0.53 0.00 (0.00%) As of 03/24/2025 Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent Oncternal Therapeutics SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView03/17/20255:04 AMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form 25Notification of the removal from listing and registration of matured, redeemed or retired securities 11/25/20245:03 AMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 10/15/202411:12 AMOncternal Therapeutics, Inc. (Subject)Oncternal Therapeutics (Subject)Yazji Salim (Reporting)Form 144Notice of proposed sale of securities pursuant to Rule 144 09/12/20243:49 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 08/08/20243:30 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 05/09/20243:17 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 05/01/202411:15 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form EFFECT04/26/20243:17 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form ARS04/26/20243:13 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form DEF 14A04/26/20243:15 PMOncternal Therapeutics, Inc. (Filer)Oncternal Therapeutics (Filer)Form DEFA14A04/10/20247:38 PMOncternal Therapeutics, Inc. (Issuer)Oncternal Therapeutics (Issuer)Wills Robert James (Reporting)Form 4Statement of changes in beneficial ownership of securities 04/01/20246:00 PMOncternal Therapeutics, Inc. (Issuer)Oncternal Therapeutics (Issuer)Wills Robert James (Reporting)Form 4Statement of changes in beneficial ownership of securities (Data available from 1/1/2016 forward) Remove Ads Related Companies and Tools Related Companies GT Biopharma 10Q Form Soligenix 10Q Form Aeterna Zentaris 10Q Form Can-Fite BioPharma 10Q Form Fresh Tracks Therapeutics 10Q Form Oragenics 10Q Form NLS Pharmaceutics 10Q Form Sonoma Pharmaceuticals 10Q Form Ensysce Biosciences 10Q Form Organovo 10Q Form SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:ONCT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.